StoxGranules India vs Onesource Specialty Pharma: share price & financials comparison
NSE: GRANULES vs ONESOURCE · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Granules India vs Onesource Specialty Pharma at a glance
Granules India (GRANULES) has a market capitalisation of ₹21,813 Cr, against ₹18,345 Cr for Onesource Specialty Pharma (ONESOURCE). Over the past year Granules India has returned +40.0%, compared with -13.7% for Onesource Specialty Pharma. Granules India earns a higher return on equity (10.9% vs -0.0%). Granules India comes out ahead on size, profitability, financial health, momentum and technicals. Onesource Specialty Pharma comes out ahead on valuation and growth. Across the scored metrics below, Granules India leads on 7 and Onesource Specialty Pharma on 5. On StoxGud's 10-point checklist, Granules India scores 8/10 and Onesource Specialty Pharma scores 4/10.
| Metric | Granules India | Onesource Specialty Pharma |
|---|---|---|
| Size | ||
| Market cap | ₹21,813 Cr | ₹18,345 Cr |
| Revenue (latest FY) | ₹5,366 Cr | ₹1,422 Cr |
| Net profit (latest FY) | ₹595 Cr | ₹-74 Cr |
| Valuation | ||
| P/E | 30.6 | — |
| P/B | 3.32 | 3.10 |
| Dividend yield | 0.17% | — |
| Profitability | ||
| Return on equity | 10.9% | 0.0% |
| Net profit margin | 12.1% | -0.1% |
| Operating margin | 22.7% | 23.5% |
| Growth | ||
| Revenue growth (YoY) | +20.3% | +37.4% |
| Net profit growth (YoY) | +39.2% | +687.0% |
| Revenue CAGR (multi-year) | +10.6% | — |
| Financial health | ||
| Debt to equity | 0.09 | 0.25 |
| Momentum | ||
| 1-month return | -5.4% | +4.7% |
| 1-year return | +40.0% | -13.7% |
| 3-year CAGR | +31.6% | — |
| 5-year CAGR | +20.2% | — |
| 10-year CAGR | +21.4% | — |
| Distance from 52W high | -12.1% | -14.8% |
| Technicals | ||
| RSI (14) | 42 | 71 |
| Price vs 200-day avg | +7.5% | +3.2% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Granules India | Onesource Specialty Pharma |
|---|---|---|
| Price above 50-day average | ✗ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✗ |
| RSI in healthy 40–70 zone | ✓ | ✗ |
| Positive 1-year return | ✓ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✗ |
| P/E below industry median | ✓ | ✗ |
| Score | 8/10 | 4/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Granules India or Onesource Specialty Pharma?
Granules India has a market cap of ₹21,813 Cr and Onesource Specialty Pharma has a market cap of ₹18,345 Cr as of 06 Nov 2026.
Which gave better returns in the last year, Granules India or Onesource Specialty Pharma?
Granules India did better: Granules India returned +40.0% and Onesource Specialty Pharma returned -13.7% over one year.
Is Granules India or Onesource Specialty Pharma a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Granules India scores 8/10 and Onesource Specialty Pharma scores 4/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.